Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
作者信息
Qi Xiaolong, Liu Yanna, Wang Jitao, Fallowfield Jonathan A, Wang Jianwen, Li Xinyu, Shi Jindong, Pan Hongqiu, Zou Shengqiang, Zhang Hongguang, Chen Zhenhuai, Li Fujian, Luo Yan, Mei Mei, Liu Huiling, Wang Zhengyan, Li Jinlin, Yang Hua, Xiang Huihua, Li Xiaodan, Liu Tao, Zheng Ming-Hua, Liu Chuan, Huang Yifei, Xu Dan, Li Xiaoguo, Kang Ning, He Qing, Gu Ye, Zhang Guo, Shao Chuxiao, Liu Dengxiang, Zhang Lin, Li Xun, Kawada Norifumi, Jiang Zicheng, Wang Fengmei, Xiong Bin, Takehara Tetsuo, Rockey Don C
机构信息
CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China
CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
出版信息
Gut. 2021 Feb;70(2):433-436. doi: 10.1136/gutjnl-2020-321666. Epub 2020 May 20.
Abstract
摘要
相似文献
1
Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.合并肝硬化的新型冠状病毒肺炎患者的临床病程及死亡危险因素：一项多中心队列研究
Gut. 2021 Feb;70(2):433-436. doi: 10.1136/gutjnl-2020-321666. Epub 2020 May 20.
2
High rates of 30-day mortality in patients with cirrhosis and COVID-19.肝硬化合并 COVID-19 患者的 30 天死亡率较高。
J Hepatol. 2020 Nov;73(5):1063-1071. doi: 10.1016/j.jhep.2020.06.001. Epub 2020 Jun 9.
3
A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019.丹麦基于人群的肝硬化合并 2019 冠状病毒病病例系列研究。
Scand J Gastroenterol. 2021 Apr;56(4):453-457. doi: 10.1080/00365521.2021.1881814. Epub 2021 Feb 16.
4
Impact of SARS CoV-2 /COVID-19 infection on the course of advanced chronic liver disease and hepatocellular carcinoma.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）/COVID-19 感染对晚期慢性肝病和肝细胞癌病程的影响。
Pharmacol Rep. 2022 Dec;74(6):1306-1314. doi: 10.1007/s43440-022-00434-4. Epub 2022 Nov 17.
5
Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort.比较肝硬化合并 COVID-19 患者与单纯肝硬化患者和单纯 COVID-19 患者的死亡率风险：多中心匹配队列研究。
Gut. 2021 Mar;70(3):531-536. doi: 10.1136/gutjnl-2020-322118. Epub 2020 Jul 13.
6
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).既往肝脏疾病与 SARS-CoV-2 感染患者的不良结局相关；APCOLIS 研究（亚太肝脏研究学会 COVID-19 肝脏损伤谱研究）。
Hepatol Int. 2020 Sep;14(5):690-700. doi: 10.1007/s12072-020-10072-8. Epub 2020 Jul 4.
7
Impact of COVID-19 on pre-existing liver disease.COVID-19 对既有肝脏疾病的影响。
Cir Cir. 2024;92(1):131-136. doi: 10.24875/CIRU.23000409.
8
Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.信件：炎症性肠病药物与严重 COVID-19 结局相关的风险-来自英国 PREPARE-IBD 多中心队列研究的令人安心的见解。
Aliment Pharmacol Ther. 2021 Jun;53(11):1236-1240. doi: 10.1111/apt.16349.
9
Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea.2019 年冠状病毒病合并肝脏疾病患者的临床结局：韩国多中心研究。
Clin Mol Hepatol. 2020 Oct;26(4):562-576. doi: 10.3350/cmh.2020.0126. Epub 2020 Oct 1.
10
Poor outcomes in patients with cirrhosis and Corona Virus Disease-19.肝硬化合并新型冠状病毒肺炎患者的不良预后
Indian J Gastroenterol. 2020 Jun;39(3):285-291. doi: 10.1007/s12664-020-01074-3. Epub 2020 Aug 15.
引用本文的文献
1
Risk factors for severe COVID-19 outcomes in the Asia-Pacific region: a literature review.亚太地区新冠重症结局的风险因素：文献综述
Front Public Health. 2025 Jun 9;13:1562179. doi: 10.3389/fpubh.2025.1562179. eCollection 2025.
2
Effectiveness and Safety of Remdesivir for the Treatment of COVID-19 Patients with Liver Cirrhosis: A Retrospective Cohort Study.瑞德西韦治疗新冠肺炎肝硬化患者的有效性和安全性：一项回顾性队列研究
Life (Basel). 2025 Mar 21;15(4):512. doi: 10.3390/life15040512.
3
Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management.新型冠状病毒肺炎相关肝损伤的研究进展：病因、诊断与治疗。
Inflammopharmacology. 2024 Oct;32(5):2649-2680. doi: 10.1007/s10787-024-01535-7. Epub 2024 Aug 10.
4
Comparative Bioinformatic Analysis Reveals Conserved Regions in SARS-CoV-2 Genome for RAPID Pandemic Response.比较生物信息分析揭示 SARS-CoV-2 基因组中的保守区域，以快速应对大流行。
Int J Mol Sci. 2024 May 25;25(11):5764. doi: 10.3390/ijms25115764.
5
Clinical characteristics of COVID-19 patients treated in emergency COVID-19 hospitals in Vietnam: Experience from Phutho province, Vietnam.越南新冠定点医院治疗的 COVID-19 患者的临床特征：来自越南富寿省的经验。
Int J Med Sci. 2024 Apr 22;21(6):1072-1078. doi: 10.7150/ijms.94461. eCollection 2024.
6
COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?2023 年关于 COVID-19、可能的肝脏途径和酒精滥用，我们了解多少？
Int J Mol Sci. 2024 Feb 12;25(4):2212. doi: 10.3390/ijms25042212.
7
Predictors of inpatient outcomes of COVID-19 infection in patients with cirrhosis in the early pandemic phase: A nationwide survey.疫情早期肝硬化患者新冠病毒感染的住院结局预测因素：一项全国性调查
JGH Open. 2023 Nov 8;7(12):889-898. doi: 10.1002/jgh3.12998. eCollection 2023 Dec.
8
Evaluation of the effects of the pandemic period on cirrhosis patients.评估大流行期间对肝硬化患者的影响。
Prz Gastroenterol. 2023;18(3):320-326. doi: 10.5114/pg.2023.131393. Epub 2023 Sep 22.
9
Impact and management of COVID-19 in liver transplant candidates and recipients.新型冠状病毒肺炎对肝移植候选者及受者的影响与管理
Ann Gastroenterol. 2023 Sep-Oct;36(5):477-489. doi: 10.20524/aog.2023.0815. Epub 2023 Jul 3.
10
COVID-19 in patients with liver disease and liver transplant: clinical implications, prevention, and management.肝病患者和肝移植受者中的新型冠状病毒肺炎：临床意义、预防与管理
Therap Adv Gastroenterol. 2023 Jul 25;16:17562848231188586. doi: 10.1177/17562848231188586. eCollection 2023.
本文引用的文献
1
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.意大利 IBD 患者中 79 例 COVID-19 的结局：一项 IG-IBD 研究。
Gut. 2020 Jul;69(7):1213-1217. doi: 10.1136/gutjnl-2020-321411. Epub 2020 Apr 30.
2
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.意大利新冠肺炎死亡患者的病死率及特征
JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683.
3
Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.血小板减少症与严重的 2019 年冠状病毒病（COVID-19）感染相关：一项荟萃分析。
Clin Chim Acta. 2020 Jul;506:145-148. doi: 10.1016/j.cca.2020.03.022. Epub 2020 Mar 13.
4
COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis.COVID-19 患者的临床特征、出院率和死亡率的荟萃分析。
J Med Virol. 2020 Jun;92(6):577-583. doi: 10.1002/jmv.25757. Epub 2020 Mar 23.
5
Liver injury in COVID-19: management and challenges.新型冠状病毒肺炎中的肝损伤：管理与挑战
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1. Epub 2020 Mar 4.
6
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
7
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
8
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
9
Liver Cirrhosis is Independently Associated With 90-Day Mortality in ARDS Patients.肝硬化与急性呼吸窘迫综合征（ARDS）患者90天死亡率独立相关。
Shock. 2016 Jan;45(1):16-21. doi: 10.1097/SHK.0000000000000487.
10
Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study.丹麦肝硬化患者的合并症与生存率：一项基于全国人口的队列研究。
Hepatology. 2008 Jul;48(1):214-20. doi: 10.1002/hep.22341.
Zotero 插件